Daxor
1 active listed funds · aggregate common net assets $0 (sum of latest reported or calculated figures) · categories: U.S. Equity · website
Funds
Recent fund news
- Daxor Accelerates Commercial Expansion of Next-Gen Blood Volume Diagnostic Platform at MedAxiom CV Transforum Fall '26 — DXR, GlobeNewsWire, Oct 15, 2026
- Daxor Announces Strong Commercial Interest and New Clinical Data at HFSA 2026 — DXR, GlobeNewsWire, Oct 14, 2026
- Daxor to Showcase Blood Volume Analysis Platform at ASN Kidney Week 2026 — DXR, GlobeNewsWire, Oct 13, 2026
- Daxor Corporation (NASDAQ:DXR) Sees Large Growth in Short Interest — DXR, Defense World, Oct 12, 2026
- Daxor to Showcase Next-Gen Blood Volume Analyzer and New Clinical Data at HFSA 2026 — DXR, GlobeNewsWire, Oct 1, 2026
- Daxor Corporation to Participate in the 10th Annual Lake Street Best Ideas Growth Conference — DXR, GlobeNewsWire, Sep 8, 2026
- Daxor Corporation CEO and President Michael Feldschuh Delivers 1st Half Corporate Update in Shareholder Letter — DXR, GlobeNewsWire, Sep 1, 2026
- Daxor Broadens Outpatient Footprint with Initiation of ezBVA Lab Diagnostic Services in Kansas — DXR, Globe News Wire, Jul 29, 2026
Sponsor, investment adviser and sub-adviser are distinct roles; this page groups funds by the sponsoring organisation named in the fund’s registration. Management biographies are not shown unless verified from official documents.